Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
about
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease
P2860
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Can we further enrich autosoma ...... OPKD score in the TEMPO trial.
@en
Can we further enrich autosoma ...... OPKD score in the TEMPO trial.
@nl
type
label
Can we further enrich autosoma ...... OPKD score in the TEMPO trial.
@en
Can we further enrich autosoma ...... OPKD score in the TEMPO trial.
@nl
prefLabel
Can we further enrich autosoma ...... OPKD score in the TEMPO trial.
@en
Can we further enrich autosoma ...... OPKD score in the TEMPO trial.
@nl
P2093
P2860
P356
P1476
Can we further enrich autosoma ...... ROPKD score in the TEMPO trial
@en
P2093
Arlene B Chapman
Christina M Heyer
Emilie Cornec-Le Gall
Frank S Czerwiec
Jaime D Blais
John Ouyang
Maria V Irazabal
Olivier Devuyst
Peter C Harris
Ron D Perrone
P2860
P304
P356
10.1093/NDT/GFX188
P407
P577
2018-04-01T00:00:00Z